Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
Background: SGLT2i directly inhibit the cardiac sodium-hydrogen exchanger-1 (NHE1) in isolated ventricular cardiomyocytes (CMs). However, other studies with SGLT2i have yielded conflicting results. This may be explained by methodological factors including cell isolation techniques, cell types and am...
| Main Authors: | Sha Chen, Cees A. Schumacher, Shirley C. M. Van Amersfoorth, Jan W. T. Fiolet, Antonius Baartscheer, Marieke W. Veldkamp, Ruben Coronel, Coert J. Zuurbier |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Physiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2023.1179131/full |
Similar Items
-
Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
by: Laween Uthman, et al.
Published: (2018-11-01) -
Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases α-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts
by: Hong Zhang, et al.
Published: (2020-12-01) -
Cardiac Sodium/Hydrogen Exchanger (NHE11) as a Novel Potential Target for SGLT2i in Heart Failure: A Preliminary Study
by: Lorena Pérez-Carrillo, et al.
Published: (2022-09-01) -
Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE/PKC/NOX axis
by: Xiaoling Li, et al.
Published: (2024-02-01) -
Direct cardiac effects of SGLT2 inhibitors
by: Sha Chen, et al.
Published: (2022-03-01)